Phase 3 Parkinson's disease trials recruiting now

All Parkinson's disease trials, every phase

Other phases for Parkinson's disease

Phase 3 Parkinson's disease trials

• A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's
  NCT04664634 · Phase: Phase 3 · Ages: 22 Years and older · Sex: All (male and female) · 1 location
• A Study of Buntanetap in Participants With PD
  NCT07284784 · Phase: Phase 2, Phase 3 · Ages: 40 Years to 85 Years · Sex: All (male and female) · 27 locations
• A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
  NCT06976268 · Phase: Phase 2, Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 22 locations
• A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
  NCT07174310 · Phase: Phase 3 · Ages: 50 Years to 85 Years · Sex: All (male and female) · 192 locations
• A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
  NCT06944522 · Phase: Phase 3 · Ages: 45 Years to 75 Years · Sex: All (male and female) · 43 locations
• Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial
  NCT07207057 · Phase: Phase 3 · Ages: 30 Years and older · Sex: All (male and female) · 2 locations
• Effect of Synbiotic as an Adjuvant Therapy in the Treatment of Parkinson's Disease
  NCT05576818 · Phase: Phase 3 · Ages: 45 Years to 65 Years · Sex: All (male and female) · 1 location
• Fexofenadine as Adjuvant Therapy in Parkinson Disease
  NCT06785298 · Phase: Phase 2, Phase 3 · Ages: 50 Years to 70 Years · Sex: All (male and female) · 1 location
• Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease
  NCT07151378 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 7 locations
• Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach
  NCT07316296 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Safinamide vs Placebo for Pain in Patients With Parkinson's Disease and Motor Fluctuations
  NCT07761936 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• VG081821AC Tablets for Early to Mid-stage Parkinson's Disease
  NCT07725562 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• [18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
  NCT06120049 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 4 locations

Common questions

What does Phase 3 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.